Zemaira market forecast points to steady growth through 2035

Nov. 20, 2026
Zemaira market forecast points to steady growth through 2035
By AI, Created 17:30 UTC, Nov 20, 2026, AGP -

The Business Research Company says the global Zemaira market is set for continued expansion through 2035, driven by rising alpha-1 antitrypsin deficiency awareness, lung disease prevalence, and broader use of augmentation therapy. North America is expected to remain the largest market as clinical research and respiratory care spending continue to rise.

Why it matters: - Zemaira is tied to treatment for alpha-1 antitrypsin deficiency, a rare condition linked to serious lung damage and emphysema. - Growth in the market reflects broader demand for respiratory care, rare-disease therapies, and plasma-derived medicines. - The report frames Zemaira as part of a wider shift toward earlier diagnosis and longer-term management of chronic lung disease.

What happened: - The Business Research Company released its "Zemaira Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035" on November 20, 2026. - The report says the Zemaira market has grown steadily in recent years and is positioned for further expansion during the forecast period. - The company also made a free sample available through its website with a direct download link: Download a free sample of the Zemaira market report.

The details: - Zemaira is an intravenous alpha1-proteinase inhibitor used as chronic augmentation therapy for adults with alpha 1-antitrypsin deficiency and emphysema. - The treatment raises functional A1-PI protein levels in the bloodstream. - Higher A1-PI levels help protect lung tissue, slow lung damage, and improve respiratory function. - The report says historical growth was supported by greater awareness of alpha-1 antitrypsin deficiency, advances in plasma fractionation, growth in specialty respiratory clinics, better diagnostic screening, and early adoption of augmentation therapy. - The forecast period is expected to benefit from rising investment in rare disease treatments, stronger demand for sustained respiratory care, expanding specialty pharmacy networks, a greater focus on personalized respiratory treatment, and innovation in plasma protein therapies. - The report highlights wider use of augmentation therapy, more attention to rare respiratory conditions, increased reliance on plasma-derived products, better monitoring of long-term respiratory health, and greater emphasis on early diagnosis. - A major growth driver is the rising prevalence of lung diseases, including asthma, pneumonia, COPD, and lung cancer. - Factors contributing to higher lung disease prevalence include tobacco use, polluted air, occupational exposure, and respiratory infections. - The report cites Australian Institute of Health and Welfare data showing 2.8 million Australians, or 11% of the population, were living with asthma in 2022. - The same data set says asthma accounted for 2.5% of total disease burden, 35% of respiratory disease burden in 2023, and 467 deaths in 2022. - Another growth factor is the increase in clinical trials focused on safety and efficacy for new treatments. - The report cites ABPI data showing UK pharmaceutical industry trials rose from 411 in 2022 to 426 in 2023. - The report includes regional coverage across Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - North America is projected to remain the dominant region in 2025, supported by advanced healthcare infrastructure, higher investment in respiratory disease management, and strong clinical research activity. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report includes contact details for Saumya Sahay and Oliver Guirdham, along with The Business Research Company website and social media links. - The source also includes a LinkedIn link for the company: The Business Research Company on LinkedIn.

Between the lines: - The report’s growth case is built less on Zemaira alone and more on broader structural demand for rare-disease care and respiratory medicine. - Clinical trial growth matters because it can speed evidence generation, support regulatory progress, and expand physician confidence in treatment use. - North America’s lead suggests the market remains concentrated where diagnostic access, specialty care, and reimbursement systems are strongest.

What's next: - The report expects the market to keep expanding through 2035 as diagnosis improves and specialty treatment networks widen. - Continued investment in rare disease therapies and plasma protein innovation could support additional adoption. - Market direction will likely track lung disease prevalence, clinical research activity, and the pace of early diagnosis.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Australia Globe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Australia Globe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.